Joseph L. Hooley's most recent trade in Idexx Laboratories, Inc. was a trade of 49 Common Stock done at an average price of $558.8 . Disclosure was reported to the exchange on July 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 558.80 per share. | 30 Jul 2026 | 49 | 325 (0%) | 0% | 558.8 | 27,381 | Common Stock |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 525 | 525 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 234 | 234 | - | - | Deferred Stock Unit | |
| Idexx Laboratories | Joseph L. Hooley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 158 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Joseph L. Hooley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 158 | 276 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 560.79 per share. | 30 Apr 2026 | 43 | 118 (0%) | 0% | 560.8 | 24,114 | Common Stock |
| Aptiv | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2026 | 5,572 | 27,869 (0%) | 0% | 0 | Ordinary Shares | |
| Aptiv | Joseph L. Hooley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.12 per share. | 28 Apr 2026 | 518 | 22,297 (0%) | 0% | 59.1 | 30,624 | Ordinary Shares |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 670.47 per share. | 30 Jan 2026 | 36 | 75 (0%) | 0% | 670.5 | 24,137 | Common Stock |
| Exxon Mobil | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,500 | 23,000 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 628.54 per share. | 30 Oct 2025 | 39 | 39 (0%) | 0% | 628.5 | 24,513 | Common Stock |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 364 | 364 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 158 | 158 | - | - | Restricted Stock Unit | |
| Aptiv | Joseph L. Hooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2025 | 6,097 | 22,009 (0%) | 0% | 0 | Ordinary Shares | |
| Aptiv | Joseph L. Hooley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.28 per share. | 22 Apr 2025 | 195 | 15,912 (0%) | 0% | 52.3 | 10,195 | Ordinary Shares |
| Exxon Mobil | Joseph Hooley L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 2,500 | 20,500 (0%) | 0% | 0 | Common Stock |